Citigroup Inc. raised its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) by 3,124.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 51,042 shares of the company’s stock after acquiring an additional 49,459 shares during the quarter. Citigroup Inc. owned approximately 0.16% of Entrada Therapeutics worth $690,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in TRDA. Tower Research Capital LLC TRC bought a new stake in shares of Entrada Therapeutics during the third quarter valued at approximately $40,000. Fred Alger Management LLC purchased a new stake in shares of Entrada Therapeutics in the 3rd quarter worth about $283,000. Bank of New York Mellon Corp grew its position in shares of Entrada Therapeutics by 60.6% in the 1st quarter. Bank of New York Mellon Corp now owns 21,933 shares of the company’s stock worth $206,000 after buying an additional 8,276 shares during the period. Swiss National Bank bought a new position in shares of Entrada Therapeutics in the 4th quarter worth about $358,000. Finally, State Street Corp increased its stake in shares of Entrada Therapeutics by 10.3% during the third quarter. State Street Corp now owns 33,294 shares of the company’s stock valued at $525,000 after purchasing an additional 3,100 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.
Entrada Therapeutics Stock Up 6.7 %
Shares of NASDAQ TRDA opened at $12.21 on Friday. Entrada Therapeutics, Inc. has a twelve month low of $5.99 and a twelve month high of $24.38. The firm has a market cap of $405.37 million, a PE ratio of -4.81 and a beta of -0.82. The business has a fifty day simple moving average of $13.53 and a two-hundred day simple moving average of $14.13.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on TRDA shares. William Blair reiterated an “outperform” rating on shares of Entrada Therapeutics in a report on Wednesday, March 22nd. HC Wainwright initiated coverage on shares of Entrada Therapeutics in a report on Monday, April 3rd. They issued a “buy” rating and a $25.00 price target on the stock.
Insiders Place Their Bets
In other news, CEO Dipal Doshi sold 2,000 shares of the business’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $13.71, for a total transaction of $27,420.00. Following the sale, the chief executive officer now directly owns 202,069 shares of the company’s stock, valued at $2,770,365.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 3,961 shares of Entrada Therapeutics stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $18.00, for a total transaction of $71,298.00. Following the completion of the transaction, the insider now owns 171,325 shares in the company, valued at approximately $3,083,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $13.71, for a total transaction of $27,420.00. Following the transaction, the chief executive officer now directly owns 202,069 shares of the company’s stock, valued at $2,770,365.99. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,053 shares of company stock valued at $165,835. Insiders own 7.58% of the company’s stock.
Entrada Therapeutics Company Profile
Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
Read More
- Get a free copy of the StockNews.com research report on Entrada Therapeutics (TRDA)
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
- Salesforce: Time to Snap it Up as the Market Buys the Dip?
Want to see what other hedge funds are holding TRDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating).
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
